Futura Medical PLC (LON:FUM) shares jumped 16% on Wednesday after the firm revealed positive data from a pharmacokinetic study of MED2002, its topical gel for erectile dysfunction (ED), which contains glyceryl trinitrate (GTN) as its active ingredient.
The AIM-listed firm said the results confirm that increasing the GTN dose beyond 0.2% will result in broadly dose-related higher concentrations in the bloodstream, which supports the company’s strong belief that the higher dose forms of MED2002 should improve efficacy, particularly in the more severe cases of ED.
READ: Futura Medical encouraged by interim data
Futura Medical said GTN demonstrated a rapid rate of absorption and was first detected in blood plasma in four to five minutes, reaching peak levels in the bloodstream within 10 to 12 minutes for all doses.
The company said in a statement that it is reviewing the implications of the detailed study data with regard to the planning of the Phase III studies for MED2002, and expects to make a further announcement on this shortly.
James Barder, chief executive of Futura Medical, said: “The results show the effectiveness of our DermaSys transdermal technology and demonstrate the potential of MED2002 as a rapid and safe treatment option for erectile dysfunction.”
He added: “We look forward to taking these excellent, supportive results into our future clinical programme.”
In early morning trading, Futura shares were up 16.2% to 37.75p.